Sarepta Therapeutics (SRPT) Liabilities and Shareholders Equity (2010 - 2026)

Sarepta Therapeutics' Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $3.2 billion for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 8.27% year-over-year to $3.2 billion in Q1 2026; TTM through Mar 2026 was $13.7 billion, a 5.2% decrease from a year earlier, with the FY2025 full-year figure at $3.3 billion, down 15.48% from the prior year.
• Liabilities and Shareholders Equity eased to $3.2 billion in Q1 2026 per SRPT's latest filing, from $3.3 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $4.0 billion in Q4 2024 and bottomed at $3.0 billion in Q2 2022.
• The 5-year median for Liabilities and Shareholders Equity is $3.2 billion (2024), against an average of $3.3 billion.
• Across the five-year window, Liabilities and Shareholders Equity increased 21.4% in 2024 and declined 15.48% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $3.1 billion in 2022, then grew by 4.35% to $3.3 billion in 2023, then climbed by 21.4% to $4.0 billion in 2024, then retreated by 15.48% to $3.3 billion in 2025, then dropped by 5.1% to $3.2 billion in 2026.
• Per Business Quant, the three latest SRPT Liabilities and Shareholders Equity figures stand at $3.2 billion (Q1 2026), $3.3 billion (Q4 2025), and $3.5 billion (Q3 2025).